Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy
Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy
About this item
Full title
Author / Creator
Publisher
England: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
Erythrodermic psoriasis (EP) is the most serious type of psoriasis with high morbidity and mortality. First-line recommended therapies for EP, cyclosporine and infliximab have significant adverse effects. Cyclosporine increases the risk of hypertension, leucopenia, infections and renal failure. Infliximab increases the risk of reactivation of tuber...
Alternative Titles
Full title
Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6357920
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6357920
Other Identifiers
ISSN
1757-790X
E-ISSN
1757-790X
DOI
10.1136/bcr-2018-226959
